To see the other types of publications on this topic, follow the link: Sinopharm.
Journal articles on the topic 'Sinopharm'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Sinopharm.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Moghnieh, Rima, Wajdi Haddad, Nayla Jbeily, et al. "Immunogenicity and real-world effectiveness of COVID-19 vaccines in Lebanon: Insights from primary and booster schemes, variants, infections, and hospitalization." PLOS ONE 19, no. 9 (2024): e0306457. http://dx.doi.org/10.1371/journal.pone.0306457.
Full textAbstract:
In this study, we conducted a case-control investigation to assess the immunogenicity and effectiveness of primary and first booster homologous and heterologous COVID-19 vaccination regimens against infection and hospitalization, targeting variants circulating in Lebanon during 2021–2022. The study population comprised active Lebanese military personnel between February 2021 and September 2022. Vaccine effectiveness (VE) against laboratory-confirmed SARS-CoV-2 infection and associated hospitalization was retrospectively determined during different variant-predominant periods using a case-control study design. Vaccines developed by Sinopharm, Pfizer, and AstraZeneca as well as Sputnik V were analyzed. Prospective assessment of humoral immune response, which was measured based on the SARS-CoV-2 antispike receptor binding domain IgG titer, was performed post vaccination at various time points, focusing on Sinopharm and Pfizer vaccines. Statistical analyses were performed using IBM SPSS and GraphPad Prism. COVID-19 VE remained consistently high before the emergence of the Omicron variant, with lower estimates during the Delta wave than those during the Alpha wave for primary vaccination schemes. However, vaccines continued to offer significant protection against infection. VE estimates consistently decreased for the Omicron variant across post-vaccination timeframes and schemes. VE against hospitalization declined over time and was influenced by the variant. No breakthrough infections progressed to critical or fatal COVID-19. Immunogenicity analysis revealed that the homologous Pfizer regimen elicited a stronger humoral response than Sinopharm, while a heterologous Sinopharm/Pfizer regimen yielded comparable results to the Pfizer regimen. Over time, both Sinopharm’s and Pfizer’s primary vaccination schemes exhibited decreased humoral immunity titers, with Pfizer being a more effective booster than Sinopharm. This study, focusing on healthy young adults, provides insights into VE during different pandemic waves. Continuous research and monitoring are essential for understanding vaccine-mediated immune responses under evolving circumstances.
2
Qaqish, Arwa, Manal Mohammad Abbas, Mohammad Al-Tamimi, Manal Ahmad Abbas, Mariam Al-Omari, and Rami Alqassieh. "SARS-CoV-2 Antinucleocapsid Antibody Response of mRNA and Inactivated Virus Vaccines Compared to Unvaccinated Individuals." Vaccines 10, no. 5 (2022): 643. http://dx.doi.org/10.3390/vaccines10050643.
Full textAbstract:
Comparative studies of SARS-CoV-2 antinucleocapsid (anti-N) antibody response in the context of inactivated virus vaccines versus natural infection are limited. This study aims to determine and compare the anti-N antibody levels in people vaccinated with Sinopharm’s (Wuhan, China) inactivated virus vaccine in comparison with naturally infected unvaccinated and Pfizer’s spike (S) mRNA-based vaccinated subjects. Two hundred ninety-nine Jordanian adults participated in the study including unvaccinated COVID-19-infected patients (n = 99), Pfizer-vaccinated (n = 100), and Sinopharm-vaccinated recipients (n = 100). Serum samples were assayed for anti-N IgG, anti-N IgM, and anti-S IgG. Sera of 64.6% of naturally infected unvaccinated participants had positive anti-S IgG (median = 36.35 U/mL; range: 0.04–532.5 U/mL) compared to 88% of Pfizer-vaccinated (Manhattan, NY, USA) (median = 26.52 U/mL; range: 0.39–1265 U/mL) and 58% of Sinopharm-vaccinated subjects (median = 14.35 U/mL; range: 0.39–870.17 U/mL). Samples of 60.6% of naturally infected unvaccinated people had positive anti-N IgG (median = 15.03 U/mL; range: 0–265.1 U/mL) compared to 25% of Pfizer-vaccinated (median = 0.02 U/mL; range: 0–68 U/mL) and 48% of Sinopharm-vaccinated subjects (median = 0.8 U/mL; range: 0–146.3 U/mL). Anti-N titers among the three groups were significantly different (p < 0.05). Anti-N IgM antibodies appeared in 23.2% of the naturally infected unvaccinated group (median = 0.29 U/mL; range: 0–15 U/mL) compared to only 9.0% of Pfizer-vaccinated (median = 018 U/mL; range: 0–33 U/mL) and 7.0% of Sinopharm-vaccinated subjects (median = 0.2 U/mL; range: 0–12.02 U/mL). A significant negative correlation was found between anti-S and age for both vaccines and between anti-S and the presence of chronic disease in Sinopharm-vaccinated subjects. A significant positive correlation between anti-N and anti-S titers was found among the three groups. This study shows that the inactivated virus vaccine, Sinopharm, induces an anti-N response that can boost that of natural infection or vice versa. On the other hand, the Pfizer mRNA-based vaccine induces a significantly stronger anti-S Ab response.
3
M Gbaj, Abdul, Emhemmed Ali Elgallal, Inass A Sadawe, et al. "Immunogenicity and Safety of Sinopharm Covid-19 Vaccine in Young Mice." International Journal of Clinical Case Reports and Reviews 10, no. 3 (2022): 01–03. http://dx.doi.org/10.31579/2690-4861/185.
Full textAbstract:
Background and Aim: Vaccines to prevent SARS-CoV-2 infection may be considered a promising way for reduction of the pandemic. Many different vaccines have become obtainable for use in many countries. The present study aims to evaluate the immune response and the safety of Sinopharm COVID-19 vaccine on 14 days old mice. Materials and Methods:Our experimental study was performed on two weeks old mice, selected by random allocation. The mice were divided into three groups of 12. Group one received asingle dose of 0.5 ml Sinopharm COVID-19 vaccine, group two received two doses of 0.5 ml Sinopharm COVID-19 vaccine, and group three (control) received two doses of 0.5 ml of 0.9 % NaCl. Results: Our study shows that Sinopharm COVID-19 vaccine is safe and induces good immunity in young mice. Conclusions: The Sinopharm COVID-19 vaccine was safe and immunogenic in 14 days old mice. The two doses of Sinopharm COVID-19 vaccine elicit a safe antibody response in young mice. Further post-marketing toxicity studies are required to assess potential hazards for children to evaluate the histopathological characteristics.
4
Pareja Cruz, Arturo, Julio César Luque Espino, Nilo Bonifacio Morales, Omar Neyra Colchado, and Joel De León Delgado. "Vacuna Sinopharm… tres años después." Horizonte Médico (Lima) 24, no. 3 (2024): e2390. http://dx.doi.org/10.24265/horizmed.2024.v24n3.00.
Full text
5
Sahibzada Syed Masood us Syed, Abid Ali Ranjha, Sidra Ghazanfer, et al. "Prevalence and predictors for adverse effects of Sinopharm and Sinovac COVID-19 Vaccines." Professional Medical Journal 29, no. 11 (2022): 1701–7. http://dx.doi.org/10.29309/tpmj/2022.29.11.7116.
Full textAbstract:
Objective: To see the prevalence and potential predictors for side effects of Sinopharm and Sinovac COVID-19 vaccines among students of medical, and BS human nutrition and dietetics courses. Study Design: Cross-sectional Proforma-derived. Setting: Sialkot Medical College, Sialkot, Pakistan. Period: July and August, 2021. Material & Methods: Fifty students (MBBS = 30; Dietetics course = 20) with at least one dose of Sinopharm or Sinovac COVID-19 vaccine were recruited, purposively. The subjects were asked to report in an indigenously designed proforma on adverse effects using recall methodology for open time. Results: Forty nine subjects gave complete responses in the proforma. The rate of adverse effects increased from 75% (n = 3) against Sinopharm to 100% (n = 9) against Sinovac vaccine among 13 students of Dietetics who had only 1st dose. For rest of the 36 participants, the rate was found, as: 76.5% (n = 13) against each of the 1st and 2nd dose of Sinopharm; 78.9% (n = 15) against 1st and 68.4 (n = 13) against 2nd doses of Sinovac vaccine. The frequency of different adverse effects per individual ranged 1-3 (Sinopharm) or 1-4 (Sinovac). Whereas, lower rate of injection site pain was recorded on 1st dose of Sinopharm than Sinovac (52.9 vs 57.9%, respectively). None of the variables was noted as potential predictor for the side effects (p >.05). Conclusion: Sinopharm, and Sinovac COVID-19 vaccines exhibit almost similar prevalence of self-manageable side effects. Moreover, there is no predictor for the effects.
6
Rauf, Muhammad Abdur, Yasir Arafat, Iqtidar-Ud Din, Syed Tahir Shah, Sumia ., and Sajjad Ullah Khan. "Short Terms Safety of Chinese Origin Covid-19 Vaccine in Cardiac Patients." Pakistan Journal of Medical and Health Sciences 16, no. 5 (2022): 1585–87. http://dx.doi.org/10.53350/pjmhs221651585.
Full textAbstract:
Objective: To find out short terms safety of Chinese origin Covid-19 vaccines in cardiac patients. To identify frequency of major and minor cardiovascular events in Covid-19 vaccinated cardiac patients. Methodology: It was a cross sectional study conducted in Qazi Hussain Ahmad Medical Complex Nowshera and Kuwait Teaching Hospital Peshawar, Pakistan from February 2021 to April 2021 on a sample of 325 cardiac patients irrespective of their gender. Cardiac patients who received 2 doses of sinopharm vaccine were included in our study. The clinical characteristics of patients included age, gender, comorbids like diabetes and hypertension and those patient s who have undergone any cardiac procedures i-e post CABG and post PCI. The data was analyzed with SPSS version Results: Total 325 known cardiac patients who received 2 doses of sinopharm vaccine were enrolled in the study, among them 198 were male and 127 were female. Participants age range was 56.48±5.9 years and among them mean age of male was 56.59±6.55 years and of female was 57.64±4.27 years. Among the participants 76(23.3%) were hypertensive out of which 44(22.2%) were male. Total number of diabetics were 98(30.15%) among which 59(29.79%) were male. Post CABG patients were 56(17.23%) in number, and among these 34(17.17%) were male. Among them 176(54.15%) were post PCI and among these 102(51.51%) were male. Out of total 325 participants the frequency of major adverse cardiovascular events was 4(1.2%) which include major cardiovascular events , death of any cause, urgent repeat revascularization, MI (not revascularized) an ischemic stroke were 1.2%, 0.91%, 0.31%, 0.92%, 0% respectively. Frequency of minor adverse cardiovascular events in cardiac patients after sinopharm vaccination was 4(1.2%) out of total 325 participants. which include minor cardiovascular events(9.85%), atrial fibrillations(0.92%), complete heart block(0%), increase in angina functional class(2.46%), increase in NYHA functional class(2.53%), and palpitations(3.69%). Conclusion: Chinese origin covid-19 vaccine (sinophorm) is safe in cardiac patients and has minor side effects and rare major side effects in cardiac patients. Keywords: Sinopharm vaccine, Cardiac patients, Corona virus
7
Alqassieh, Rami, Aiman Suleiman, Sami Abu-Halaweh, et al. "Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers." Vaccines 9, no. 11 (2021): 1223. http://dx.doi.org/10.3390/vaccines9111223.
Full textAbstract:
COVID-19 (coronavirus disease 2019) vaccines induce immunity through different mechanisms. The aim of this study is to compare the titers of specific antibodies in subjects vaccinated with either the Pfizer-BioNTech COVID-19 vaccine or the Sinopharm vaccine. This prospective observational cohort included Jordanian adults vaccinated with two doses, 21 days apart, of either of the two aforementioned vaccines. Titers were collected 6 weeks after the administration of the second dose. Overall, 288 participants were included, of which 141 were administered the Pfizer-BioNTech vaccine, while 147 were administered the Sinopharm vaccine. Remarkably, 140 (99.3%) of the Pfizer-BioNTech vaccine recipients had positive IgG titers, while 126 (85.7%) of Sinopharm recipients had positive IgG (p < 0.001). The mean titer for IgG among Pfizer-BioNTech recipients was 515.5 ± 1143.5 BAU/mL, compared to 170.0 ± 230.0 BAU/mL among Sinopharm subjects (p < 0.001). Multivariable regression analysis showed that the Pfizer-BioNTech vaccine positively correlated with positive IgG titers (OR: 25.25; 95% CI: 3.25–196.15; p = 0.002), compared with a negative effect of cardiovascular diseases (OR: 0.33; 95% CI: 0.11–0.99; p = 0.48) on IgG titers. In conclusion, fully vaccinated recipients of the Pfizer-BioNTech vaccine had superior quantitative efficiency compared to Sinopharm recipients. A booster dose is supported for Sinopharm recipients, or those with chronic immunosuppressive diseases.
8
Martinez Oliva, Brenda Gisela, Elma Rossell, Denisse Ulloa, Dayana Pamela Bello Kopa, and Ricardo Enrique Grados Torrez. "RESPUESTA INMUNE HUMORAL CONTRA SARS-COV-2 OTORGADA POR SPUTNIK V Y SINOPHARM EN POBLACIÓN BOLIVIANA." Orbis Tertius - UPAL 8, no. 15 (2024): 90–105. http://dx.doi.org/10.59748/ot.v8i15.147.
Full textAbstract:
Introducción: Las vacunas anti-SARS-CoV-2 inducen la producción de anticuerpos neutralizantes tipo IgG contra el Dominio de Unión al Receptor (RBD) de la proteína S del virus. En Bolivia, las vacunas Sinopharm y Sputnik V fueron ampliamente utilizadas durante la pandemia, sin embargo, existen pocos datos sobre la inmunidad humoral en población boliviana vacunada. Objetivo: Comparar la respuesta humoral conferida contra SARS-CoV-2 por las vacunas Sinopharm y Sputnik V, mediante cuantificación de IgG anti-RBD, producidos por individuos bolivianos, tras 21 días del cumplimiento del esquema completo de vacunación. Materiales y Métodos: Se incluyeron 231 personas vacunadas con Sinopharm y 420 con Sputnik V. La medición de IgG anti-RBD se realizó por ELISA. Resultados: El 87,9 y 88,8 % de las personas vacunadas con Sinopharm y Sputnik V, respectivamente, fueron positivos para IgG anti-RBD. De acuerdo a la edad, las personas mayores de 69 y 59 años vacunadas con Sinopharm y Sputnik V, correspondientemente, mostraron niveles más bajos de IgG anti-RBD en comparación con personas más jóvenes (p<0,0001). Para ambas vacunas, no hubo diferencias significativas en los niveles de anticuerpos entre hombres y mujeres, sin embargo, los vacunados con Sputnik V reportaron niveles más altos de IgG anti-RBD en comparación con los vacunados con Sinopharm (p<0,0001). Conclusiones: Sinopharm y Sputnik V generan protección humoral en población boliviana, aunque existe disminución significativa en el nivel de IgG anti-RBD en mayores a 69 y 59 años de edad respectivamente. Fecha de recepción: 03/08/2023. Fecha de evaluación: 15/04/2024. Fecha de aprobación: 17/05/2024.
9
Boshra, Marian S., Raghda R. S. Hussein, Marwa Mohsen, et al. "A Battle against COVID-19: Vaccine Hesitancy and Awareness with a Comparative Study between Sinopharm and AstraZeneca." Vaccines 10, no. 2 (2022): 292. http://dx.doi.org/10.3390/vaccines10020292.
Full textAbstract:
Background: Awareness about the COVID-19 vaccine’s adverse effects is crucial for gaining public trust. As we still lack proof of vaccines’ safety, this survey aimed to investigate Egyptians’ general awareness of the Sinopharm and AstraZeneca vaccines against COVID-19 and provide considerable evidence on their side effects and complications. Methods: A cross-sectional questionnaire-based study was conducted in Egypt between 20 September and 10 October in 2021, with multiple-choice questions (MCQs) covering all data on vaccine administration confusion, adverse effects or intensity, and complications. Results: Among the 390 participants, 42.3% reported being hesitant before receiving one of the vaccines. About 40.3% of participants were previously infected before getting vaccinated while only 4.6% reported being infected after vaccination. The AstraZeneca vaccine demonstrated higher side effects and symptoms than the Sinopharm vaccine while the Sinopharm vaccine showed a significantly higher rate of COVID-19 infection after vaccination. Conclusions: People with higher educational levels and chronic respiratory diseases represent an excellent model for accepting COVID-19 vaccination. A booster shot is recommended for people vaccinated with the Sinopharm vaccine due to a significantly higher rate of COVID-19 infection after vaccination; however, the Sinopharm vaccine shows a more acceptable safety profile.
10
Meo, Sultan Ayoub, Riham A. ElToukhy, Anusha Sultan Meo, and David C. Klonoff. "Comparison of Biological, Pharmacological Characteristics, Indications, Contraindications, Efficacy, and Adverse Effects of Inactivated Whole-Virus COVID-19 Vaccines Sinopharm, CoronaVac, and Covaxin: An Observational Study." Vaccines 11, no. 4 (2023): 826. http://dx.doi.org/10.3390/vaccines11040826.
Full textAbstract:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging viral zoonotic illness that has developed a distinctive and threatening situation globally. Worldwide, many vaccines were introduced to fight against the COVID-19 pandemic. The present study aims to compare the bio-pharmacological characteristics, indications, contraindications, efficacy, and adverse effects of inactivated whole-virus COVID-19 vaccines, Sinopharm, CoronaVac, and Covaxin. Initially, 262 documents and 6 international organizations were selected. Finally, 41 articles, fact sheets, and international organizations were included. The data were recorded from the World Health Organization (WHO), Food and Drug Administration (FDA) USA, Web of Science, PubMed, EMBASE, and Scopus. The results demonstrated that these three inactivated whole-virus COVID-19 vaccines, Sinopharm, CoronaVac, and Covaxin, received emergency approval from the FDA/WHO, and all three of these vaccines are beneficial for the prevention of the COVID-19 pandemic. The Sinopharm vaccine has been recommended during pregnancy and for people of all age groups, and the CoronaVac and Covaxin vaccines are recommended for people over 18 years of age and older. These three vaccines have recommended intramuscular doses of 0.5 mL each, with a 3–4 week interval. These three vaccines can be stored in a refrigerator at +2 to +8 °C. The common adverse effects of these vaccines are pain at the injection site, redness, fatigue, headache, myalgias, general lethargy, body ache, arthralgia, nausea, chills, fever, and dizziness. The overall mean efficiency for the prevention of the COVID-19 disease is 73.78% for Sinopharm, 70.96% for CoronaVac, and 61.80% for Covaxin. In conclusion, all three inactivated whole-virus COVID-19 vaccines, Sinopharm, CoronaVac, and Covaxin, are beneficial for the prevention of the COVID-19 pandemic. However, evidence suggests that the overall impact of Sinopharm is slightly better than that of CoronaVac and Covaxin.
11
Jawad, Mahmood J., Mohammed J. Jawad, Iman Sabeeh Hasan, Saif M. Hassan, Ghizal Fatima, and Najah R. Hadi. "EVALUATION OF COVID-19 VACCINES EFFICACY IN IRAQI PEOPLES." Wiadomości Lekarskie 75, no. 4 (2022): 929–37. http://dx.doi.org/10.36740/wlek20220420102.
Full textAbstract:
The aim: The present study was carried out on patients recovered from COVID-19, including those patients who have taken vaccine and those who have not. Materials and methods: The patients were recruited via an online panel and surveyed at different regions of Iraq from June 1, 2021, to August 30, 2021. Results: Our results demonstrated that the highest percentage of people recommended Pfizer vaccine followed by Sinopharm, while AstraZeneca vaccine was least recommended. Conclusions: The efficacy of different vaccines differed significantly; the highest effectiveness was observed with Pfizer vaccine followed by AstraZeneca and Sinopharm with effectiveness ranging from 94%, 89%, and 74%, respectively. Further, the highest percentage of re-infected patients was observed with Sinopharm vaccine followed by Astra Zeneca and Pfizer vaccine, respectively. Also, the highest percent of re-infection with masking used was seen in the case of Sinopharm vaccine followed by AstraZeneca and Pfizer vaccine. Although, we observed that post-vaccination symptoms were lowest than pre-vaccination symptoms, the percent of asymptomatic cases post-vaccination was highest than pre-vaccination cases for all vaccines.
12
Katamesh, Basant E., Moustafa E. Katamesh, W. A. Abdalrhman, et al. "Awareness, Practice, and Acceptance of COVID-19 Vaccination among Medical Students from Mansoura University, Egypt: A Cross-sectional Survey." Epidemiology and Health System Journal 9, no. 3 (2022): 133–38. http://dx.doi.org/10.34172/ijer.2022.23.
Full textAbstract:
Background and aims: The coronavirus disease 2019 (COVID-19) is an emerging transmissible infection that can be prevented by proper hygiene measures and vaccination. With the rise and rapid spread of the Omicron variant, vaccines are currently the best protective measure. This cross-sectional study aimed to assess knowledge, practice, and attitude towards COVID-19 virus and vaccines, particularly Sinopharm, among medical students in Mansoura University, Egypt, from July to September 2021. Methods: A cross-sectional study was conducted using a 35-item questionnaire covering demographic data. COVID-19 knowledge/practice and knowledge/attitude towards vaccines were distributed on medical students’ university Facebook group. A score was calculated for knowledge (KS), practice (PS), and attitude (AS). A 60% cutoff was considered satisfactory, and the statistical analysis was carried out using one-way ANOVA, linear regression, and Pearson’s coefficient. Results: A total of 837 students participated in this study. The majority (73.12%) of participants showed satisfactory COVID-19 KS and Sinopharm AS (54.77%) but unsatisfactory PS (68.99%) and Sinopharm KS (62.75%). Knowledge had a significant effect on Sinopharm vaccine acceptance. Moreover, females indicated higher COVID-19 KS and PS, whilst males showed higher Sinopharm KS and AS. Gender and year group had a strong correlation with PS. Furthermore, the majority (92.4%) accepted vaccination and believed it should be mandatory (80.41%). The selected vaccines were Pfizer (44.84%)>AstraZeneca (33.86%)>Sinopharm (15.56%)>others. Efficacy, safety, and country of production were the main predictors of vaccine choice. More than half (59.48%) stated that the country in which the vaccine is produced is important when choosing their intended vaccine, and 20.87% stated that their decision is based on vaccine efficacy. Conclusions: COVID-19 was a challenging pandemic; there are several available COVID-19 vaccines, but the most available in Egypt is the Sinopharm vaccine. The results of this study will provide a basis regarding the knowledge and attitude of medical students who play a crucial part in the cycle of infection. These results will help outline the main causes of misunderstandings that can be solved by providing educational needed interventions, implementing protective measures, and distributing scientifically correct data.
13
Shahid, Rizwana, Muhammad Umar, Muhammad Mujeeb Khan, Shazia Zeb, Ayesha Nadar, and Sheema Afzal. "Side effects of Sinopharm Vaccine experienced by healthcare professionals of Holy Family Hospital, Rawalpindi, Pakistan." Journal of Rawalpindi Medical College 25, no. 1 (2021): 67–71. http://dx.doi.org/10.37939/jrmc.v25i1.1645.
Full textAbstract:
Objectives: To determine the gender and age based disparities in side effects among healthcare workers in response to COVID-19 (Sinopharm) vaccination
 Subjects & Methods: Total 216 healthcare workers were vaccinated against COVID-19 by administering Sinopharm vaccine during February and March 2021 at Infectious Diseases Department of Holy Family Hospital Rawalpindi were enrolled in the study through consecutive sampling. Data for this cross-sectional descriptive study was gathered pertinent to age, gender and side effects of Sinopharm vaccination. The information regarding vaccination side effects was inquired through telephonic calls. Data was analyzed by means of SPSS version 25.0.
 Results: Mean age of healthcare workers in our study was 35.7 ± 9.5 years. Most (54.6%) of them were females. About 79.2% of health professionals were 21-40 years old. Side effects after first dose of Sinopharm vaccine were experienced by 46.3% males and 42.4% females. About 45.2% and 42.3% males and females respectively overlooked the second jab adversity. Greater proportion (43.6%) complained of vaccine related side effects after the second dose than 37.5% subjects who noted side effects after the first dose of vaccine. Bodyaches, injection site pain, headache and fever were established as the commonest post-vaccination side effects.
 Conclusion: Side effects resulting from Sinopharm vaccine among our healthcare personnel were minimal. Fortunately none of them complained of serious aftereffects. Despite the COVID vaccination, our healthcare workers should strictly adhere to COVID SOPs amidst pandemic in order to avoid catastrophe in future.
14
Altaf, Shandana Altaf, Mariana Amer Amer, and Amer Azhar Azhar. "THE SAFETY OF VEROCELL COVID -19 (SINOPHARM) VACCINATION AMONG HEALTH CARE WORKERS IN KHYBER TEACHING HOSPITAL, PESHAWAR." Journal of Medical Sciences 29, no. 03 (2021): 99–103. http://dx.doi.org/10.52764/jms.21.29.3.8.
Full textAbstract:
Objectives: To determine the safety of Sinopharm Covid -19 vaccine among health care workers of Khyber Teaching Hospital (KTH, Peshawar).
 Material and Methods: This observational study was carried out to assess the side effects associated with the first dose of Sinopharm vaccine among health care workers in KTH Peshawar, Pakistan. Data was collected using a close ended questionnaire which was filled by the health care workers above 18 years of age. The participants were asked to monitor any side effects upto 1 week after the first dose of sinopharm vaccine administered to them. Data was analyzed using SPSS version 23 for macbook.
 Results: A total of 400 health workers were included in the study but only 155 partcipants responded by completing the questionnaire. It was observed that 63.9% of the participants who were vaccinated experienced at least one symptom after vaccination. The most common symptom was pain at injection site (36.8%) experienced during 15 – 30 minutes after vaccination. The occurrence of symptoms after vaccination was greater in age group 24-42 years which was 60.6% while in age group 43-60 years it was 39.4%. Our analysis shows that there is no association between co-morbidities and post vaccination symptoms (p>0.01).
 Conclusion: Our study concludes that sinopharm vaccine has no severe/ moderate side effects and therefore safe for public use.
 Key words: Safety, SARS Covid-19, Sinopharm vaccine
15
De Silva, Shamila Thivanshi, Dileepa Senajith Ediriweera, Wathsala Wimalasena, et al. "Evaluation of BBIBP-CorV Sinopharm COVID-19 vaccine effectiveness in Sri Lanka: a test-negative case control study." BMJ Open 14, no. 11 (2024): e090341. http://dx.doi.org/10.1136/bmjopen-2024-090341.
Full textAbstract:
ObjectivesThere is limited research on real-world effectiveness of BBIBP-CorV Sinopharm COVID-19 vaccine. This study evaluated real-world effectiveness of Sinopharm vaccine in Sri Lanka by assessing absolute vaccine efficacy.Design and settingA retrospective test-negative case-control study was conducted at ten large government hospitals across the country.ParticipantsConsecutive adults aged ≥18 years attending outpatient departments who tested reverse-transcription-PCR positive for SARS-CoV-2 during the study period were recruited.Main outcome measuresAn interviewer-administered questionnaire was administered, and outcome of COVID-19 infection was assessed in cases.ResultsOf 1829 recruited, 914 (49.9%) were male, and mean age was 45.2 (SD 15.3) years; 1634 (89.3%) were vaccinated with two doses of BBIBP-CorV Sinopharm vaccine, while 195 (10.1%) were vaccine-naïve. Compared with the vaccinated, unvaccinated persons were older but otherwise similar in their demographic and medical profiles. Unvaccinated were more likely to have fever, shortness of breath and vomiting as symptoms and were more likely to seek treatment. Significantly more vaccinated individuals received treatment at home. After admission, the unvaccinated were more likely to receive oxygen. Significantly more unvaccinated persons died of COVID-19 compared with the vaccinated. Sinopharm vaccine was 78.2% (94% CI 69.0% to 85.0%) effective at preventing COVID-19 infection, 88.7% (81.6%–93.2%) effective at preventing severe infection and 85.6% (69.6%–93.6%) effective at preventing death.ConclusionsBBIBP-CorV Sinopharm vaccine is effective at mitigating severity of illness and reducing the likelihood of hospitalisation, severe illness and death, in those who received primary vaccination, compared with the unvaccinated.
16
Deznabi, Nazila, Nasrin Abolhasanpour, and Hanieh Salehi-Pourmehr. "Coma Following the Sinopharm COVID-19 Vaccine: A Case Report." Biomedical Research Bulletin 1, no. 2 (2023): 87–89. http://dx.doi.org/10.34172/biomedrb.2023.16.
Full textAbstract:
The Chinese Sinopharm vaccine was produced in 2020 as an effective preventive measure against COVID-19. The low and non-serious adverse effects of the Sinopharm COVID-19 vaccine were reported in the literature. This report presents a 70-year-old man who underwent surgical burr-hole evacuation of the hematoma in the right and left parietal and frontal areas. Six days after discharge from the hospital, he received Sinopharm vaccine, and three days post-vaccination, he was referred to the hospital with signs of weakness and lethargy. During the hospitalization, the patient had extensive tonic-clonic seizures and then went into a coma. A close follow-up was done for clinical, laboratory, and imaging studies during his stay in the hospital. After 10 days of appropriate medication, the seizure stopped.
17
Yadegarynia, Davood, Shabnam Tehrani, Fahimeh Hadavand, et al. "Side Effects of COVID-19 Vaccination Among Healthcare Workers in Tehran, Iran." International Journal of Medical Toxicology and Forensic Medicine 13, no. 3 (2023): 40536. http://dx.doi.org/10.32598/ijmtfm.v13i3.40536.
Full textAbstract:
Background: Since the emergence of coronavirus disease 2019 (COVID-19), many people have been vaccinated worldwide. Despite the preventive role of vaccines, their side effects face disease management with challenges. This study aims to investigate the side effects of COVID-19 vaccination among healthcare workers in Tehran, Iran. Methods: This cross-sectional study was conducted from April to October 2022 on 377 healthcare workers in Tehran, Iran. Data collection was carried out through an interview by a researcher using a checklist assessing systemic and local side effects of COVID-19 vaccines. Results: The mean age of participants was 36.03±10.24 years, and 68.2% were female. Participants experienced significantly more local (26.5% vs. 14.3%, P<0.001) and systemic (52.0% vs. 31.8%, P<0.001) side effects after the first dose than after the second dose. After the first dose, AstraZeneca (45.9%) caused significantly more local reactions than Sputnik V (21.7%) and Sinopharm (14.5%). AstraZeneca (83.7%) caused significantly more systemic side effects than Sputnik V (50.7%) and Sinopharm (14.5%). The prevalence of local and systemic side effects after the first dose was significantly different in terms of vaccine types (P<0.001). After the second dose, AstraZeneca (20.4%) caused significantly more local reactions than Sputnik V (12.8%) and Sinopharm (10.5%) (P<0.001). Additionally, AstraZeneca (38.8%) and Sputnik V (37.4%) caused significantly more systemic side effects than Sinopharm (7.9%) (P<0.001). Conclusion: Most healthcare workers in Tehran experienced flu-like symptoms and local reactions at the injection site after vaccination against COVID-19, mainly after the first dose. They had more side effects after vaccination with AstraZeneca and Sputnik V, compared to Sinopharm.
18
Al-Khazrajy, Drgam Flah Ismael, and Qussay Nouri Raddam. "Evaluation of the Efficacy of COVID-19 Vaccines (Pfizer, Astra Zeneca, Sinopharm) Using Iraqi Local Samples." NeuroQuantology 20, no. 4 (2022): 73–81. http://dx.doi.org/10.14704/nq.2022.20.4.nq22097.
Full textAbstract:
Subject: The current study was aimed to evaluate the efficacy of the three approved vaccines in Iraq (Pfizer, AstraZeneca, and Sinopharm). By detecting the IgG and IgM antibody to the first subunit of the structural spike protein (S1), which is responsible for binding the virus to the angiotensin-converting enzyme receptor (ACE-2) on the surfaces of most cells of the body. Object: Study include 44 samples which were divided into four groups of samples. Each group had (11) samples. The first group of people consisted of those who had received both the first and second dose of Pfizer vaccine after 30 or more days the second group of people who had received the first and second dose of AstraZeneca vaccine after 30 or more days, the third group of people who had received the first and second dose of Sinopharm vaccine after 30 days or more, and the control group Which included people recovering from COVId-19 disease, all samples were collected from of Baghdad city-Iraq. Result: The results indicated the superiority of the Pfizer vaccine over the AstraZeneca and Sinopharm vaccines when compared with the control group, The average Pfizer vaccine concentration was (106.8 ± 16.2), while the AstraZeneca vaccine showed a weak superiority with an average concentration of (79.65 ± 14.33) compared to the control group, for which the average concentration of IgG-S1 was (64.55 ± 14.6). While the concentration of the Sinopharm vaccine was (70.94 ± 8.77), it did not show a significant difference compared to the control group. Conclusion: Our result showed that all vaccines (Pfizer, AstraZeneca, and Sinopharm) used in this study were able to stimulate the production of antibodies against (SARA0COV2), and the Pfizer vaccine was the most effective and immunization.
19
Tanveer, Hira, Sehrish Zaffar, Muhammad Osama, et al. "Comparative IgG Antibody Titers Following Second Dose of Sinopharm and Pfizer Vaccination." BioMedica 39, no. 4 (2023): 178–82. http://dx.doi.org/10.24911/biomedica/5-675.
Full textAbstract:
<p><strong>Background and Objective: </strong>The vaccines Sinopharm and Pfizer account for more than 7.3 billion vaccinations across the globe. Study data shows that the protection offered by these vaccines wanes with time, which is why the third dose of a different or same vaccine may become necessary. The objective of this study was to compare the levels of IgG in the post-vaccination phase, with two different vaccines, Sinopharm and Pfizer.&nbsp;&nbsp;</p>
 <p><strong>Methodology: </strong>A cross sectional study was conducted at CMH Lahore Medical College and Institute of Dentistry, after approval by the Ethical committee. A total of 100 participants, who were completely vaccinated, with either Sinopharm or Pfizer, at least six weeks before, were included in the study. Participants with concurrent infection, incomplete vaccination or any known disease, were excluded from the study. Written consent was obtained from all the participants. A predesigned questionnaire, adapted from similar studies, was used for data collection. Afterwards, blood samples were collected and IgG antibody levels were estimated using RD-RatioDiagnostics SARS-COV-2 virus IgG ELISA kit (E-COG-K105). The collected data was analyzed with SPSS software. Results with p value &lt; 0.05 were taken as significant.</p>
 <p><strong>Results: </strong>Mean age of the participants was 20.18&plusmn;1.29 years. Mean antibody titers, six weeks post-vaccination, were 5453.73&plusmn;609.15 U/ml and 10786.86&plusmn;1525.49 U/ml in Sinopharm and Pfizer groups, respectively. The difference was statistically significant (p=0.0004).</p>
 <p><strong>Conclusion: </strong>Antibody response is considerably higher in Pfizer-vaccinated individuals, in comparison to Sinopharm.</p>
20
Nayyef Mustafa, Khalidah. "A statistical study about vaccines used against Covid-19 in Nineveh Governorat Iraq." Public Health of Indonesia 10, no. 4 (2024): 49–55. https://doi.org/10.36685/phi.v10i4.864.
Full textAbstract:
Background:A total of 518 individuals vaccinated with three different COVID-19 vaccines were included in this study. The majority received the Pfizer vaccine, which was associated with mild side effects, while others experienced more severe symptoms such as headache and fever. Objective:To evaluate the types of COVID-19 vaccines administered, the age distribution of vaccinated individuals, and the vaccines' efficiency and safety, assessed by two criteria: prevention of reinfection and reduction of side effects. Methods:A cross-sectional study was conducted using a structured questionnaire from June 2021 to January 2022. Data were collected through in-person interviews, verification of vaccine cards, and personal information, followed by statistical analysis of the gathered data. Results:The most vaccinated age group was 36–50 years. The distribution of vaccines administered included Pfizer (86.4%), AstraZeneca (8.5%), and Sinopharm (5.4%). Vaccine effectiveness, based on the absence of reinfection post-vaccination, was highest for Pfizer (90.1%), followed by AstraZeneca (86.4%) and Sinopharm (78.6%). Adherence to preventive and sterilization measures was observed among vaccinated individuals, with 31.3% adhering completely and 49.4% adhering partially. Conclusion:The vaccines studied included Pfizer, AstraZeneca, and Sinopharm. The most vaccinated age group was 36–50 years, while the least vaccinated group comprised individuals over 50 years. All vaccines demonstrated mild side effects, with Pfizer being the most effective, followed by AstraZeneca and Sinopharm. Keywords:COVID-19 vaccines; age groups; vaccine safety; adherence post-vaccination
21
Jeewandara, J. M. K. Chandima, Inoka Sepali Aberathna, Saubhagya Danasekara, et al. "Comparison of the Immunogenicity of five COVID-19 vaccines in Sri Lanka." Journal of Immunology 208, no. 1_Supplement (2022): 65.01. http://dx.doi.org/10.4049/jimmunol.208.supp.65.01.
Full textAbstract:
Abstract We assessed antibody responses 3 months post-vaccination in those who received mRNA-1273 (n=225), Sputnik V (n=128) or the first dose of Gam-COVID-Vac (n=184) and compared the results with previously reported data of Sinopharm and AZD1222 vaccinees. 99.5% of Moderna &gt;94% of AZD1222 or Sputnik V, 72% to 76% of Gam-COVID-Vac (first dose) and 38.1% to 68.3% of Sinopharm vaccinees had ACE2 blocking antibodies above the positive threshold. The ACE2 blocking antibody levels were highest to lowest was Moderna &gt; Sputnik V/AZD1222 (had equal levels)&gt; first dose of Gam-COVID-Vac &gt; Sinopharm. All Moderna recipients had antibodies above the positive threshold to the ancestral (WT), B.1.1.7, B.1.351.1 and 80% positivity rate for B.1.617.2. Positivity rates of Sputnik V vaccinees for WT and variants, were higher than AZD1222 vaccinees, while Sinopharm vaccinees had the lowest positivity rates (&lt;16.7%). These findings highlight the need for further studies to understand the effects on clinical outcomes. Allergy, Immunology and Cell Biology Unit, University of Sri Jayewardenepura; the NIH, USA (grant number 5U01AI151788-02), UK Medical Research Council and the Foreign and Commonwealth Office for support. T.K.T. is funded by the Townsend-Jeantet Charitable Trust (charity number 1011770) and the EPA Cephalosporin Early Career Researcher Fund. A.T. are funded by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant no. 2018-I2M-2-002).
22
Jeewandara, Chandima, Inoka Sepali Aberathna, Shashika Dayarathna, et al. "Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection." PLOS ONE 17, no. 10 (2022): e0274845. http://dx.doi.org/10.1371/journal.pone.0274845.
Full textAbstract:
The kinetics and magnitude of antibody responses to different proteins of the SARS-CoV-2 virus in Sinopharm/BBIBP-CorV vaccinees has not been previously studied. Therefore, we investigated antibody responses to different SARS-CoV-2 proteins at 2 weeks, 3 months, and 6 months post-second dose in previously infected (n = 20) and uninfected (n = 20) Sinopharm/BBIBP-CorV vaccinees. The IgG antibodies to the S, S1 and S2 and N were several folds higher in those who had natural infection compared to uninfected individuals at all time points. We then compared the persistence of antibody responses and effect of natural omicron infection or BNT162b2 booster in Sinopharm/BBIBP-CorV vaccinees. We measured the total antibodies to the RBD, ACE2 blocking antibodies and antibody responses to different SARS-CoV-2 proteins in Sinopharm vaccinees at 7 months post second dose, including those who remained uninfected and not boosted (n = 21), or those who had previous infection and who did not obtain the booster (n = 17), those who were not infected, but who received a BNT162b2 booster (n = 30), or those who did not receive the booster but were infected with omicron (n = 29). At 7 months post second dose uninfected (no booster) had the lowest antibody levels to the RBD, while omicron infected vaccinees showed significantly higher anti-RBD antibody levels (p = 0.04) than vaccinees who received the booster. Only 3/21 cohort A (14.3%) had ACE2 blocking antibodies, while higher frequencies were observed in naturally infected individuals (100%), those who received the booster (18/21, 85.7%), and omicron infected individuals (100%). Pre-vaccination, naturally infected had the highest antibody levels to the N protein. These data suggest that those previously infected Sinopharm/BBIBP-CorV vaccinees have a robust antibody response, 7 months post vaccination, while vaccinees who were naturally infected with omicron had a similar immune response to those who received the booster. It will be important to investigate implications for subsequent clinical protection.
23
Haneen, Saad Mohammed Khasbak, Shkhair Al-Janabi Hayder, and Jawad Kadhim Mohaned. "Evaluation of CBC in Different Vaccines Types of COVID-19." INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND BIO-MEDICAL SCIENCE 03, no. 07 (2023): 381–86. https://doi.org/10.5281/zenodo.8190349.
Full textAbstract:
In December 2019, Wuhan reported its first cases of pneumonia which called coronavirus disease 2019 (COVID-19), a single-stranded RNA virus. COVID-19 vaccine is a safe way to help the immune system build defenses against COVID-19. The immune system relies on various types of cells, such as Lymphocytes, monocytes, macrophages, and other immune cells to fight infections. The aim of the study is to the assessment of blood parameters in different vaccinated groups of COVID-19 vaccines. We collected 100 samples from individuals that vaccinated with AstraZeneca, Sinopharm, and Pfizer vaccines and unvaccinated (infected), which were divided into four groups, each containing 25 samples, and did a CBC test. The study results indicate that different COVID-19 vaccines and natural immunization result in diverse immune responses in males and females. In males, the Sinopharm vaccine stimulates higher white blood cell count (7.11±0.44s) with a significant difference (<em>p<0.05</em>), while the AstraZeneca vaccine triggers greater lymphocyte (LYM%) activation (34.3±0.99) with a significant difference (<em>p<0.05</em>) than others covid19 vaccines. Natural immunization leads to increased monocyte (MON%) levels (8.34±0.69) with a significant difference <em>(p<0.05)</em> compared to covid19 vaccines in which the Sinopharm vaccine (6.96±0.49) shows significantly lower monocyte activation. The Pfizer and Sinopharm vaccines induce higher granulocyte (GRA%) activation (60.34±1.88 and 60.28±1.63, respectively) with a significant difference <em>(p<0.05)</em>, while natural immunization (55.87±3.8) shows lower activation compared to covid19 vaccines with a significant difference <em>(p<0.05)</em>. While in females, The AstraZeneca, Sinopharm vaccines, and natural immunization (6.1±0.5, 6.89±0.68, and 6.26±0.52, respectively) had the higher white blood cell (WBC) number with no significant difference<em>(p>0.05)</em> among them, while the Pfizer vaccine (5.7±0.36) had the lower WBC with a significant difference (p<0.05). The AstraZeneca vaccine had higher lymphocytes (LYM%) (36.14±1.25) with a significant difference <em>(p<0.05)</em>, while the Sinopharm vaccine had significantly lower (29.85±3.62). Natural immunization had a significantly higher MON% (8.11±1.28a) with <em>(p<0.05) </em>compared to covid19 vaccines (with no significant difference among them), while the Sinopharm vaccine showed a higher in both GRA% and GRA number (64.38±3.88 and 4.52±0.57, respectively) with a significant difference <em>(p<0.05)</em>. In conclusion, the AstraZeneca vaccine elevated the lymphocytes (LYM%) while natural immunization increased (MON%) in both genders. The study also reveals that males and females exhibit varied immune responses to different COVID-19 vaccines and natural immunization, and these variations may be attributed to vaccine composition, mechanisms of action, immune response variability, and timing of the research.
24
Nirujan, K., K. Jayasundara, and U. Dissanayake. "Guillain- Barré Syndrome (GBS) after Sinopharm vaccination." Jaffna Medical Journal 34, no. 1 (2022): 45. http://dx.doi.org/10.4038/jmj.v34i1.157.
Full text
25
Iftikhar, Anwaar, Muhammad Farooq Sabar, Quart ul Ain Ahmad, Rida Farooq, and Mubeen Akhtar. "Different Covid-19 Vaccines in Pakistan: Administration and Effectiveness." National Journal of Health Sciences 8, no. 3 (2023): 132–36. http://dx.doi.org/10.21089/njhs.83.0132.
Full textAbstract:
Pfizer-BioNTech, Moderna, Sputnik V (typically manufactured in Russia), CoronaVac (China), Sinopharm (China), Vaxzevria, and Cansino (both made in China) are among the vaccines that have been certified for emergency use in several countries. All of the above vaccinations were authorized to Pakistan, bypassing Pfizer and Moderna. The effectiveness, safety, mechanism of action, dosage, and availability of mandatory vaccines in Pakistan up to May 20, 2021. We searched PubMed and Google Scholar for all known material on COVID-19 vaccinations. We also looked at grey literature papers. Instead of Pfizer and Moderna, Pakistan has approved all the preceding vaccines. Moderna and Pfizer were determined to be the most effective among all vaccinations, with 90% effectiveness, followed by Vaxzevria, Sputnik V, Sinopharm, and Cansino. All immunizations have caused lesser bad effects like fever, injection site pain, or headaches. Further clinical studies are being done throughout the world to combat the epidemic. In large populations, public attention plays a critical role in vaccination efforts. Keywords: Covid-19, Vaccines, Sinopharm (China), Sputnik V (Russia), CoronaVac Pfizer, Moderna, Administration, Effectiveness.
26
Mortaz, Esmaeil, Neda Dalil Roofchayee, Hamidreza Jamaati, et al. "Characterization of QuantiFERON Severe Acute Respiratory Syndrome Coronavirus 2 and Anti-severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid and S1 Spike Protein Antibodies in Vaccinated and Unvaccinated Coronavirus Disease 2019 Patients." Biomedical and Biotechnology Research Journal 8, no. 3 (2024): 393–402. http://dx.doi.org/10.4103/bbrj.bbrj_251_24.
Full textAbstract:
Abstract Background: Coronavirus disease 2019 (COVID-19) vaccination has been shown to elicit both humoral (antibody) and cell-mediated (T-cell) immune responses. This study aimed to characterize and compare the QuantiFERON severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and anti-SARS-CoV-2 antibody responses in vaccinated and unvaccinated COVID-19 patients, as well as vaccinated healthy controls (HCs). Methods: A total of 96 COVID-19 patients (68 vaccinated with Sinopharm and 15 with AstraZeneca), 13 unvaccinated COVID-19 patients, and 16 vaccinated HCs (8 Sinopharm and 8 AstraZeneca) were included. Serum antibodies against the SARS-CoV-2 spike (S1) protein and nucleocapsid (N) protein were measured by enzyme-linked immunosorbent assay. T-cell responses were evaluated using the QuantiFERON assay against three SARS-CoV-2 viral antigens (Ag1, Ag2, and Ag3). Results: There were no significant differences in S1 antibody levels between COVID-19 patients (vaccinated or unvaccinated) and HCs. However, 100% of unvaccinated COVID-19 patients had anti-N antibodies, which was significantly higher than the AstraZeneca-vaccinated group. T-cell responses did not differ significantly between vaccinated and unvaccinated patients or between vaccinated patients and HCs. Vaccination with Sinopharm induced higher levels of total N antibodies and greater interferon-gamma release against the viral antigens compared to the other groups. Conclusions: Vaccination, especially with Sinopharm, induced robust humoral (N antibodies) and cellular (T-cell) immune responses in COVID-19 patients. The findings highlight the importance of vaccination in eliciting a comprehensive immune response against SARS-CoV-2, even in the context of prior infection.
27
Ghazawy, Eman R., Ashraf A. Ewis, Doaa M. Khalil, et al. "COVID-19 vaccines-related adverse events and associated factors reported among adult Egyptians." Journal of Public Health and Development 21, no. 1 (2023): 45–59. http://dx.doi.org/10.55131/jphd/2023/210104.
Full textAbstract:
COVID-19 vaccine recipients are more likely to experience post-vaccination adverse events, which are considered the source of concerns about vaccine safety. This study aims to describe the utilization of COVID-19 vaccines and the associated adverse events and their possible predictors among adult Egyptians. An online cross-sectional study was designed to collect data through a Google Form questionnaire in November 2021. Adults who received at least one dose of the COVID-19 vaccine were asked to report their experience with vaccination and associated adverse events. A total of 853 participants were included in the study after receiving Sinopharm/Sinovac (63%), AstraZeneca (27%), Pfizer-BioNTech (4.8%), and other vaccines (5.2%). Around 50% of participants thought that COVID-19 vaccines were safe, 30.8% advised others with vaccination, and 68.3% reported post-vaccination adverse events. The most commonly encountered adverse symptoms were injection site pain (82.5%), fatigue (67.4%), flu-like symptoms (59.6%), and bone and muscle pains (59.6%). Most adverse events were less likely reported by Sinopharm/Sinovac recipients than recipients of other vaccines. The significant predictors for reporting adverse events were female gender, the first dose of vaccination, and vaccine type (AstraZeneca versus Sinopharm/Sinovac) with multivariable-adjusted OR (95% CI) = 1.85 (1.34-2.54); 2.01 (1.24–3.25), and 3.86 (2.54–5.86). Findings revealed that adverse events of COVID-19 vaccines are common. Sinopharm/Sinovac recipients were reported to have lesser adverse events than other recipients. However, serious reactions were rare which ensures the safety of all vaccine types among the adult Egyptian population.
28
Razazian, Nazanin, Mohammad Ali Sahraian, Mansour Rezaei, Sharareh Eskandarieh, Seyedeh Elham Mousavi, and Negin Fakhri. "Side Effects of First and Second Doses of Inactivated COVID-19 Vaccine in Multiple Sclerosis." Caspian Journal of Neurological Sciences 9, no. 1 (2023): 1–8. http://dx.doi.org/10.32598/cjns.9.32.373.1.
Full textAbstract:
Background: It is currently recommended to vaccinate against SARS CoV-2 for people with multiple sclerosis (MS), but it is uncertain what effect it will have on people with MS (PwMS). Objectives: We aimed to compare the side effects of the first and second doses of the Sinopharm vaccine in PwMS. Materials & Methods: This descriptive-analytical follow-up study was conducted on PwMS patients in Kermanshah province, Iran, who received the Sinopharm vaccine using the nationwide MS registry of Iran (NMSRI) by available methods between May and August 2021. Using a researcher-made questionnaire, demographic and clinical information about PwMS, as well as side effects from the Sinopharm vaccine were collected by telephone 5-14 days after the first and second doses. Data were analyzed using SPSS software version 25. Results: Study participants included 188 PwMS, including 148 females (78.7%) and 40 males (21.3%). PwMS had Median age of 42.66±11.1 years and Median 9.57±7.0 for disease duration. In the 1st dose, the prevalence of side effects was significantly higher than in the second dose (58.5% vs 47.0%, P=0.012). Fatigue (30.1%), myalgia (29.8%), fever (25.0%), and headache (22.3%) were the most common in the first dose, and fatigue (27.1%), headache (18.6%), myalgia (17.5%) and fever (14.9%) were the most common in the second dose. COVID-19 was present in 51 people (27.3%) before vaccination. Conclusion: Sinopharm vaccine side effects were significantly more prevalent in the first dose than in the second dose. Most side effects are moderate in severity and transient.
29
Nawaz, Zunaira, Mariyam Zahid, Mariam Sajjad, Naveen Azhar, Noor ul Elmah Hasan, and Arooma Shaukat Siddiqui. "Short term side effects of inactivated COVID-19 vaccines among Pakistani population: a survey-based cross-sectional study." Journal of the Pakistan Medical Association 73, no. 8 (2023): 1592–97. http://dx.doi.org/10.47391/jpma.6885.
Full textAbstract:
Objective: To assess the short-term adverse effects of two inactivated coronavirus disease-2019 vaccines, and the demographic factors associated with such events. Method: The cross-sectional study was conducted in Karachi from August to October 2021 after approval from the ethics review board of Dow University of Health Sciences, Karachi, and comprised adults of either gender who had received at least one dose of either Sinopharm or CoronaVac vaccine. Data was collected using a predesigned online and printed survey forms. The questionnaire investigated the symptoms experienced by the participants after the administration of the vaccine dose. Data was analysed using SPSS 22. Results: Of the 1000 survey forms filled, 896 were analysed; 505(56.4percent) women and 391(43.6percent) men were included in the study. Most of the participants were aged 18-30 years 644(71.9percent). Overall, 581(64.8percent) subjects had received Sinopharm vaccine, and 315(35.2percent) received CoronaVac. The incidence of side effects after the first and second dose respectively was 63.3percent (368 out of 581) and 55.2percent (239 out of 433) for Sinopharm and 65.4percent (206 out of 315) and 61.4percent (89 out of 145) for CoronaVac. The factors associated with a higher risk of side effects were female gender and young age (p 0.05). Conclusion: Most of the reported symptoms were minor in nature, like pain at the injection site, and women and those of young age reported such symptoms more than men and the elderly. Key Words: COVID-19 vaccine, Side effects, Sinopharm, CoronaVac, SARS-CoV-2.
30
Khasbak, Haneen Saad, Hayder Shkhair Al-Janabi, and Mohanad Jawad Kadhim. "Assessment of Some Immunological Parameters Postvaccination with Different Types of COVID-19 Vaccines." Medical Journal of Babylon 22, no. 2 (2025): 418–25. https://doi.org/10.4103/mjbl.mjbl_1178_23.
Full textAbstract:
Abstract Background: Coronavirus disease 2019 (COVID-19) is a highly contagious viral infection that can spread rapidly worldwide. Several vaccines have been developed to combat COVID-19. Objectives: This study aimed to assess some immunological parameters, including CD8+ and IgG levels in sera of different vaccinated groups with different types of COVID-19 vaccines. Materials and Methods: The current study included 75 samples from vaccinated persons with AstraZeneca, Sinopharm, and Pfizer vaccines and 25 unvaccinated (naturally infected) persons. CD8+ and IgG levels were measured using ELISA technique. Results: The results showed that the CD8+ level increased significantly (P < 0.05) in the Pfizer vaccinated group than in Sinopharm and AstraZeneca groups, and there were no significant differences in the CD8⁺ level in the Pfizer-vaccinated group and unvaccinated group. The results also showed significant differences between CD8+ levels in males (22.78 ± 3.36) and females (9.86 ± 1.16) in Sinopharm vaccine, whereas there were no significant differences in CD8+ levels between males and females in other vaccine groups. COVID-19 IgG antibody levels were elevated significantly in unvaccinated people compared to those who received the Pfizer vaccine. In contrast, there were no significant differences in concentration of IgG antibodies between Sinopharm, AstraZeneca vaccines, and unvaccinated groups. Notably, the Pfizer vaccine exhibited significantly lower IgG levels in all age groups compared to the other vaccines. Conclusion: The Pfizer vaccine induced a cellular immune response represented by CD8+ levels than other COVID-19 vaccines and unvaccinated (naturally infected) people, while natural immunization had higher IgG by inducing a humoral immune response than COVID-19 vaccines.
31
Karimi, Mehran, Tahereh Zarei, Sezaneh Haghpanah, et al. "EFFICACY AND SAFETY OF SINOPHARM VACCINE FOR SARS-COV-2 AND BREAKTHROUGH INFECTIONS IN IRANIAN PATIENTS WITH HEMOGLOBINOPATHIES: A PRELIMINARY REPORT." Mediterranean Journal of Hematology and Infectious Diseases 14, no. 1 (2022): e2022026. http://dx.doi.org/10.4084/mjhid.2022.026.
Full textAbstract:
Background: The ongoing COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to high morbidity and mortality worldwide. Vaccination against SARS-CoV-2 is a leading strategy to change the course of the COVID-19 pandemic.
 Aims of study: Our aim was to investigate the efficacy and side effects of Sinopharm vaccine in patients with hemoglobinopathies in Iran, and the frequency of breakthrough infection after a full course of vaccination.
 Methods: A multicenter cross-sectional study of 434 patients with hemoglobinopathies (303 β-thalassemia major, 118 β-thalassemia intermedia, and 13 sickle-thalassemia) were conducted from March to July 2021 in IRAN. All patients have received the first dose of China Sinopharm vaccine and received the second dose of the vaccine 28 days apart.
 Antibody testing: Detection of immunity after vaccination was evaluated by commercial enzyme-
 linked immunosorbent assay (Pishtazteb ELISA commercial kit), including a surrogate virus
 neutralization test (sVNT), for detection of SARS-CoV-2 immunoglobulins (IgA, IgM, IgG), total neutralizing antibody (NAb).
 Results: The mean age of patients was 35.0± 8.5 (from 18 to 70) years and 55.6% were positive for antibody. Overall, 48.2% of the studied population had at least one side effect after vaccination. The most frequent side effects were fever and chills, dizziness, and body pain. A total of 90 (20.7%) vaccinated patients developed breakthrough infections after full Sinopharm vaccination. Disease severity was recorded, and it was classified as mild in 77.8%, moderate in 13.6%, and severe in 7.4% of patients. One 28-year-old woman with β- thalassemia major died eight days after the diagnosis of breakthrough SARS-CoV-2 infection.
 Discussion: No safety concerns were identified in patients who received two doses of Sinopharm vaccine. Its efficacy was not optimal which might be due to lack of its effect on new variations of virus. However, our data show that it can prevent from severity of COVID-19 infection in patients with hemoglobinopathies. The frequency of breakthrough infections after full Sinopharm vaccination support the evolving dynamic of SARS-CoV-2 variants requiring special challenge, since such infection may represent a risk for vulnerable patients.
32
Honarpisheh, Parisa, Zahra Nematollahi, Mojgan Palizdar, et al. "Short-Term Side Effects of Sinopharm Coronavirus Disease 2019 Vaccine in Adolescents Aged 12-18 Years Vaccinated in Dr. Masih Daneshvari Hospital." Journal of Preventive, Diagnostic and Treatment Strategies in Medicine 1, no. 4 (2022): 246–51. http://dx.doi.org/10.4103/jpdtsm.jpdtsm_73_22.
Full textAbstract:
BACKGROUND: Vaccination is known as one of the best approaches for overcoming the coronavirus disease 2019 (COVID-19) pandemic. Many COVID-19 vaccines were authorized for emergency use, and the knowledge about efficacy, safety, and adverse effects of COVID-19 vaccines is based only on data published from clinical trials and is not reliable. Therefore, a report of the side effects in the real world and among different populations is very helpful. The purpose of this research is to study and describe the side effects of the Sinopharm vaccine in adolescents aged 12–18 years. MATERIALS AND METHODS: A descriptive retrospective study was conducted on 502 Iranian populations aged 12–18 years who received the first dose of the Sinopharm vaccine. Information was collected based-on telephonic interviews. In this survey, participants and their parents were asked about the underlying disease, side effects developed after receiving the vaccine, the time of beginning the reactions, and the time of resolving them. RESULTS: Out of 502 vaccinated participants with a mean age of 14.2 ± 0.6 years, about 10% (n = 50) reported side effects after the Sinopharm COVID-19 vaccine. The most common side effects were injection site reactions (5.97%), and pain at the injection site (70%) was the most common of them. Systemic reactions were 2.19%, and fatigue/malaise was the most common of them (22%). The mean time to begin the side effects after injection was 42 ± 8.6 min, and the mean time of resolving developed adverse effects was 38 ± 5.3 min. CONCLUSION: About 10% of the population aged 12 to18 years developed adverse effects following the Sinopharm vaccine. These adverse reactions were often mild in severity and were developed mostly during 2 h of vaccination and resolved in <1 h and required no or home-based treatment. It seems that the Sinopharm vaccines are safe in the population aged 12–18 years and are not associated with significant complications. The exact mechanisms of these adverse reactions are not clear, but according to the time of occurrence of the vaccine side effects, it seems that type 1 hypersensitivity allergic reactions are mainly involved.
33
Bolívar Enríquez, Karina, and Janneth Romero Olañeta. "Anticuerpos Neutralizantes AntiSARS-CoV-2 en personal de salud inmunizados con la vacuna Sinopharm del Policlínico de Especialidades en Cochabamba." Revista Científica de la Seguridad Social de Corto Plazo 2, no. 1 (2023): 18–22. http://dx.doi.org/10.59918/wujk9610af76v.
Full textAbstract:
a) Objetivo: Evaluar la eficacia de la vacuna Sinopharm en la generación de anticuerpos neutralizantes contra el SARS-CoV-2 en personal de salud, y la capacidad para prevenir la enfermedad. b) Métodos: El estudio incluyo a 77 trabajadores de salud inoculados con Sinopharm. Se cuantificó la concentración de los anticuerpos neutralizantes utilizando quimioluminiscencia MAGLUMI. Variables analizadas: sexo, edad, antecedentes de infección. Análisis realizado con IBM SPSS v-24.0®. c) Resultados: Participaron un total de 77 trabajadores de salud. De ellos, el 70,1% eran del sexo femenino. La mayoría de los participantes (54,5%) se encontraron en el rango de edad de 41 a 60 años, el 44% del personal de salud tienen antecedentes de Covid-19. En cuanto a la generación de anticuerpos neutralizantes, el 70,1% de los participantes mostraron resultados positivos. Por otro lado, el 54,5 % de los participantes generaron concentraciones bajas de anticuerpos, considerados como no reactivos tras la vacunación. d) Discusión: Los resultados coinciden con investigaciones previas sobre la eficacia de la vacuna Sinopharm en la generación de anticuerpos neutralizantes. Respuesta inmunológica positiva en personal de salud, con esquema completo, la misma que estimula producción de anticuerpos y proporciona protección. e) Conclusiones: Los resultados de este estudio indican que la vacuna Sinopharm es efectiva en la generación de anticuerpos neutralizantes en el personal de salud. La mayoría de los participantes mostraron una respuesta inmunológica positiva, con un alto porcentaje de generación de anticuerpos neutralizantes. A pesar de la infección posterior a la vacunación, los síntomas no fueron graves, lo que sugiere que la vacuna puede reducir la gravedad de la enfermedad. Estos resultados respaldan la importancia de la vacunación en el personal de salud y la población en general para prevenir la enfermedad y proteger su salud.
34
Nabizadeh, Edris, Fatemeh Honarmandpour, Rezvan Mashhadizade, and Azam Honarmandpour. "Side Effects Comparison of Coronavirus Vaccines Among Healthcare Workers in Shoushtar, Iran." Clinical Pathology 16 (January 2023): 2632010X2311667. http://dx.doi.org/10.1177/2632010x231166798.
Full textAbstract:
Objective: Vaccination is one of the effective ways to fight against COVID-19 disease. Various vaccines have been designed during the coronavirus pandemic. Each of the used vaccines has beneficial effects as well as side effects. Healthcare workers were among the first vaccinated persons against COVID-19 in different countries. The current study aims to compare the side effects of AstraZeneca, Sinopharm, Bharat, and Sputnik V on healthcare workers in Iran. Methods: This descriptive study was conducted from July 2021 to January 2022 on 1639 healthcare workers who received the COVID-19 vaccines. Data were collected using a checklist that contained questions related to systemic, local, and severe side effects of the vaccine. The collected data were analyzed using the Kruskal-Wallis, Chi-square, and trend chi-square. P < .05 was regarded as a significant statistical difference. Results: The most commonly injected vaccines were Sinopharm (41.80%), Sputnik V (36.65%), AstraZeneca (17.75%), and Bharat (3.80%), respectively. At least 37.5% of participants reported one complication. The most common side effects after 72 hours of the first and second doses were as follows: injection site pain, fatigue, fever, myalgia, headache, and chill. Overall complication rates were reported as follows: AstraZeneca (91.4%), Sputnik V (65.9%), Sinopharm (56.8%), and Bharat (98.4%). Bharat showed the highest overall side effects, while Sinopharm had the lowest overall side effects. Also, our results indicated that individuals with a previous history of positive COVID-19 infection had a higher rate of overall complications. Conclusions: The majority of participants did not show life-threatening side effects after the injection of 1 of the 4 studied vaccines. Since it was well accepted and tolerable by the participants, it can be used widely and safely against SARS-CoV-2.
35
Aijaz, Khola, Fahad Fehmi, Zara Saeed, et al. "LESSONS LEARNED: AN IN-DEPTH LOOK AT SINO PHARM VACCINE RESEARCH IN KARACHI PAKISTAN OBSERVATIONAL STUDY." Insights-Journal of Life and Social Sciences 3, no. 1 (2025): 123–29. https://doi.org/10.71000/agfbta58.
Full textAbstract:
Background: The global COVID-19 pandemic has led to widespread efforts in developing effective vaccines to control the spread of SARS-CoV-2. The Sinopharm BBIBP-CorV vaccine, an inactivated virus vaccine developed by the Beijing Institute of Biological Products, received emergency use authorization from the World Health Organization (WHO). Despite its global distribution, limited real-world safety data exist for specific populations, particularly in low- and middle-income countries like Pakistan. Objective: This study aimed to evaluate the safety profile and incidence of adverse events following immunization (AEFI) associated with the Sinopharm vaccine among the population of Karachi, Pakistan. Methods: A prospective observational study was conducted over 56 days, including 5,420 participants vaccinated with the Sinopharm BBIBP-CorV vaccine. Data were collected using structured questionnaires and follow-up interviews, focusing on demographic information, comorbidities, and post-vaccination adverse effects. Descriptive statistics were applied to assess the frequency and severity of AEFI, while chi-square tests evaluated associations between adverse events and demographic factors. Results: Out of 5,420 vaccinated individuals, 24 (0.442%) reported adverse effects. Of these, 23 cases (95.8%) occurred after the first dose and 1 case (4.2%) after the second dose. Female participants accounted for 79.2% of AEFI cases, while males represented 20.8%. The most affected age group was 41–50 years, comprising 45.8% of AEFI cases. Common adverse effects included headache (41.7%), vertigo (20.8%), and dizziness (16.7%). Comorbidities such as hypertension and diabetes showed no significant association with AEFI occurrence. Conclusion: The Sinopharm vaccine demonstrated a strong safety profile, with mild and self-limiting adverse effects observed in a small fraction of participants. These findings support its continued use in mass immunization campaigns, reinforcing its role as a reliable tool against COVID-19.
36
Korsak, K. S., I. O. Stoma, E. V. Voropaev, O. V. Osipkina, and A. A. Kovalev. "Study of Humoral Immunity against Coronavirus Infection COVID-19 in Vaccinated Individuals with Vaccines Available in the Republic of Belarus (Sputnik V (Gam-COVID-Vac), RF and Sinopharm (BBIBP-CorV), PRC)." Epidemiology and Vaccinal Prevention 22, no. 1 (2023): 28–37. http://dx.doi.org/10.31631/2073-3046-2023-22-1-28-37.
Full textAbstract:
Relevance. Many countries around the world are developing effective vaccines against SARS-CoV-2. The measure of the effectiveness of the vaccination process has traditionally been antibody production. The frequency and intensity of adverse reactions is also an important factor in making a decision regarding a vaccine. This study presents the results of the evaluation of the formation of humoral immunity and the occurrence of reactions in response to the administration of Sputnik V (Gam-COVID-Vac), RF, and Sinopharm (BBIBP-CorV), PRC. Aim. Analyze immunogenicity and reactogenicity of COVID-19 vaccines used in the Republic of Belarus (Sputnik V and Sinopharm). Materials and methods. Evaluation of postvaccination immune response by enzyme immunoassay and differential enzyme immunoassay for class G immunoglobulins to S- and N-proteins SARS-CoV-2. Blood plasma of the study participants was used as biological material. Blood sampling was performed 3 times: immediately before the first vaccine dose, on day 42, and 6 months after the first vaccine dose. To evaluate the frequency and intensity of postvaccination reactions, study participants were questioned. Results. At 42 days after administration of both vaccines, antibody levels are rising, with a significantly higher quantitative IgG count for the Sputnik V vaccine. This trend is also observed 6 months after the first dose of both vaccines, both among those previously infected with SARS-CoV-2 and those without a history of COVID-19. The comparison of Sputnik V and Sinopharm vaccine groups in terms of IgG (BAU/ml) levels to S- and N-proteins revealed a statistically significant difference in IgG levels to S-protein: the Sputnik V vaccine group had significantly higher IgG levels to S-protein than the Sinopharm vaccine group (p = 0.0000196). The incidence of adverse reactions in this study was 45%. All reactions noted were mild to moderate in severity. The most common were soreness and redness at the injection site, elevated body temperature, and a combination of several reactions. The increased body temperature after vaccination was more common among those vaccinated with the Sputnik V vaccine. Conclusion. Compared to Sinopharm, Sputnik V vaccine produces higher antibody level. Adverse reactions were observed in both vaccinated groups. However, significant statistical differences were found with regard to fever in the Sputnik V vaccine group, which occurred more frequently.
37
Boualila, L., B. Mrini, A. Tagmouti, et al. "Sinopharm COVID-19 vaccine-induced Stevens–Johnson syndrome." Journal Français d'Ophtalmologie 45, no. 4 (2022): e179-e182. http://dx.doi.org/10.1016/j.jfo.2021.12.005.
Full text
38
Admin, Prof Dr Sahibzada Masood Us Syed, Imran Idrees Butt, Shiza Ehtasham, et al. "ADVERSE EFFECTS OF SINOVAC AND SINOPHARM COVID-19 VACCINES SEEN IN UNIVERSITY STUDENTS." Sial Journal of Medical Sciences 1, no. 3 (2023): 26–32. http://dx.doi.org/10.60127/sjms.v1i3.13.
Full text
39
Sohag, Kazi, Anna Gainetdinova, Shawkat Hammoudeh, and Riad Shams. "Dynamic Connectedness among Vaccine Companies’ Stock Prices: Before and after Vaccines Released." Mathematics 10, no. 15 (2022): 2812. http://dx.doi.org/10.3390/math10152812.
Full textAbstract:
This study investigates the interconnectedness among the stocks of the publicly listed vaccine-producing companies before and after vaccine releases in 2020/21. In doing so, the study utilizes the daily frequency equity returns of the major vaccine producers, including Moderna, Pfizer, Johnson & Johnson, Sinopharm and AstraZeneca. First, the investigation applies the TVP-VAR Dynamic Connectedness approach to explore the time–frequency connectedness between the stocks of those vaccine producers. The empirical findings demonstrate that Moderna performs as the most prominent net volatility contributor, whereas Sinopharm is the highest net volatility receiver. Interestingly, the vaccine release significantly increases the stock market connectedness among our sampled vaccine companies. Second, the cross-quantile dependency framework allows for the observation of the interconnectedness under the bearish and bullish stock market conditions by splitting any paired variables into 19 quantiles when considering short-, medium- and long-memories. The results also show that a high level of connectivity among the vaccine producers exists under bullish stock market conditions. Notably, Moderna transmits significant volatility spillovers to Sinopharm, Johnson & Johnson and AstraZeneca under both the bearish and bullish conditions, though the volatility transmission from Moderna to Pfizer is less pronounced. The policy implication proposes that the vaccine release allows companies to increase their stock returns and induce substantial volatility spillovers from company to company.
40
Sarker, Protim, Evana Akhtar, Rakib Ullah Kuddusi, et al. "Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population." Vaccines 10, no. 9 (2022): 1498. http://dx.doi.org/10.3390/vaccines10091498.
Full textAbstract:
Background: The adaptive immune response is a crucial component of the protective immunity against SARS-CoV-2, generated after infection or vaccination. Methods: We studied antibody titers, neutralizing antibodies and cellular immune responses to four different COVID-19 vaccines, namely Pfizer-BioNTech, Moderna Spikevax, AstraZeneca and Sinopharm vaccines in the Bangladeshi population (n = 1780). Results: mRNA vaccines Moderna (14,655 ± 11.3) and Pfizer (13,772 ± 11.5) elicited significantly higher anti-Spike (S) antibody titers compared to the Adenovector vaccine AstraZeneca (2443 ± 12.8) and inactivated vaccine Sinopharm (1150 ± 11.2). SARS-CoV-2-specific neutralizing antibodies as well as IFN-γ-secreting lymphocytes were more abundant in Pfizer and Moderna vaccine recipients compared to AstraZeneca and Sinopharm vaccine recipients. Participants previously infected with SARS-CoV-2 exhibited higher post-vaccine immune responses (S-specific and neutralizing antibodies, IFN-γ-secreting cells) compared to uninfected participants. Memory B (BMEM), total CD8+T, CD4+ central memory (CD4+CM) and T-regulatory (TREG) cells were more numerous in AstraZeneca vaccine recipients compared to other vaccine recipients. Plasmablasts, B-regulatory (BREG) and CD4+ effector (CD4+EFF) cells were more numerous in mRNA vaccine recipients. Conclusions: mRNA vaccines generated a higher antibody response, while a differential cellular response was observed for different vaccine types, suggesting that both cellular and humoral responses are important in immune monitoring of different types of vaccines.
41
Abu-Halaweh, Sami, Rami Alqassieh, Aiman Suleiman, et al. "Qualitative Assessment of Early Adverse Effects of Pfizer–BioNTech and Sinopharm COVID-19 Vaccines by Telephone Interviews." Vaccines 9, no. 9 (2021): 950. http://dx.doi.org/10.3390/vaccines9090950.
Full textAbstract:
Vaccines are considered the best approach for countering the COVID-19 pandemic. In this study, we compared early side effects associated with vaccination with the Sinopharm and Pfizer–BioNTech COVID-19 vaccines. Participants of this observational cohort were interviewed based on semi-structured telephone interviews, with enquiries about side effects that developed after vaccination with each dose of these vaccines. Overall, 1004 participants were enrolled, of which 51.1% received Sinopharm vaccine and 48.9% received the Pfizer–BioNTech vaccine. After the first dose, 46.3% of participants had an adverse reaction, with injection site pain most commonly being reported (33.2%). Participants who received the Pfizer–BioNTech vaccine had significantly higher frequencies of all types of adverse reactions (p < 0.01), with no significant differences in the duration of adverse reactions between the two vaccines. Regarding the second dose, 48.6% of participants had adverse reactions, with injection site pain being most commonly reported (29%). Those who received the Pfizer vaccine reported higher frequencies of all adverse reactions (p < 0.01). However, a longer duration of adverse reactions was seen among Sinopharm vaccine recipients as compared to Pfizer–BioNTech vaccine recipients (p = 0.01). In conclusion, early adverse effects are reported following all types of vaccines but these are more likely to be encountered following the administration of new-generation vaccines. These side effects are mostly mild and treatable.
42
ZAHRA, SS, S. DARS, S. KUMARI, B. SAHAR, A. WAHID, and ST EJAZ. "ANTIBODY RESPONSE TO THE COVID-19 VACCINE AMONG PREGNANT WOMEN: A PROSPECTIVE STUDY." Biological and Clinical Sciences Research Journal 2023, no. 1 (2023): 191. http://dx.doi.org/10.54112/bcsrj.v2023i1.191.
Full textAbstract:
The study's objective was to investigate the antibody responses and fetal and maternal adverse effects of the Sinopharm vaccine. A prospective study was conducted in The Gynaecology Department of LUMHS Hospital Jamshoro, Hyderabad, Multan and DG Khan from January 2021 to January 2022. A total of 90 women were included in the study who were administered Sinopharm. 3/90 (3.3%) women received shots in 1st trimester, 56/90 (62%) in 2nd trimester and 31/90 (34%) in 3rd trimester. ELISA measured SARS-CoV-2 receptor binding domain (RBD) specific total antibodies and ACE2 blocking antibodies. The adverse effects on the mother and fetus were evaluated after the delivery. The vaccine administration showed no harmful effects or pregnancy-related complications like congenital anomalies, miscarriage, preterm delivery, thrombotic events, fetal death, or hypertensive disorders. SARS-CoV-2 specific total antibodies were found in 57/90 (63%) women at the time of recruitment (when receiving 1st dose); thus, they were considered to be previously infected. The whole sample was seroconverted after 2nd dose. Significantly high levels of RBD binding antibodies and ACE2 blocking antibodies were observed in previously infected women after administration of the second dose compared to uninfected individuals. The Sinopharm vaccine showed positive results in pregnant women and induced high seroconversion rates and ACE2-blocking antibodies in 2nd and 3rd trimester.
43
Naseer, Aqsa, Madeeha Nazar, Jamila Khan, et al. "Recurrence of COVID-19 Infection in Healthcare Workers after complete Vaccination." Pakistan Journal of Medical and Health Sciences 16, no. 10 (2022): 208–10. http://dx.doi.org/10.53350/pjmhs221610208.
Full textAbstract:
Background: COVID-19 is a novel infection. Since its first case report in 2019, it has affected population globally. Healthcare workers are at most risk as they are in direct contact with patients. Aim: To record recurrence of symptomatic COVID 19 after complete doses of Sinopharm vaccine among healthcare workers. Study design: Descriptive case series Place and duration of study: Department of Gastroenterology, Holy Family Hospital, Rawalpindi from 12th December 2021 to 11th June 2022. Methodology: Twenty four healthcare workers and between 20-60 years who had COVID-19 infection previously and despite receiving two doses of Sinopharm vaccine, again developed symptomatic COVID-19 diseases were enrolled. The severity was graded as per guidelines provided by CEAG. The extent of exposure during work was documented. Results: No significant association was found with any of the healthcare workers with duration and extent of vaccination. Upto 66% of the front line workers got COVID at 5th month and no considerable variation was noticed in other months of the vaccination. Similarly, three PGs also got COVID at 5th month and at 5th month highest number of frontline workers got COVID-19. Conclusion: COVID-19 reinfection can occur even after vaccination though symptoms remain relatively mild and Sinopharm provides protection against severe infection for prevention of COVID-19. Keywords: COVID, Recurrence, Health workers, Vaccination, Infection
44
Meo, Anusha Sultan, Adeeba Masood, Usama Shabbir, et al. "Adverse Effects of Sinopharm COVID-19 Vaccine among Vaccinated Medical Students and Health Care Workers." Vaccines 11, no. 1 (2023): 105. http://dx.doi.org/10.3390/vaccines11010105.
Full textAbstract:
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease caused a highly problematic situation worldwide. Various vaccines were launched to combat the COVID-19 pandemic. This study aims to investigate the adverse effects of first and second doses of the Sinopharm vaccine among vaccinated medical and dental students and healthcare workers. A well-established questionnaire was distributed online, and 414 medical and dental students and healthcare workers (HCW) comprising 355 females (85.7%) and 59 males (14.3%) participated; all were vaccinated with two doses of Sinopharm. The most common side effect was pain at the injection site after dose one in 253 respondents (61.3%) and after dose two in 161 respondents (38.9%). Other symptoms included general lethargy in 168 (40.6%), myalgia/body pain in 99 (23.9%), low-grade fever in 93 (22.4%), and headache in 87 (21%) respondents. Common side effects reported after the second dose of the vaccine following pain at the injection site included general lethargy in 21.3% (88), headache in 10.4% (43), myalgia/body pain in 9.9% (41), and low-grade fever in 6.1% (25) of the respondents. In conclusion, common adverse effects of the Sinopharm vaccine were pain at the injection site, general lethargy, myalgia, body pain, low-grade fever, and headache. These adverse effects were mild in intensity for both doses but slightly more frequent and severe for the first dose than the second dose.
45
Abutaleb, Mohammed H., Hafiz A. Makeen, Abdulkarim M. Meraya, et al. "Risks of Cardiac Arrhythmia Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis." Vaccines 11, no. 1 (2023): 112. http://dx.doi.org/10.3390/vaccines11010112.
Full textAbstract:
This systematic review and meta-analysis aimed to summarize the current evidence regarding the association between coronavirus disease 2019 (COVID-19) vaccination and the risk of cardiac arrhythmia. MEDLINE, via PubMed and OVID, Scopus, CENTRAL, and Web of Science were searched using the relevant keywords to identify the relevant citations. Comprehensive Meta-analysis and Review Manager 5.4.1 were used for all the statistical analyses. Seventeen studies (n = 567,033,087 patients) were included. The pooled analysis showed that the incidence of cardiac arrhythmia post-COVID-19 vaccination with Pfizer, Moderna, AstraZeneca, CoronaVac, and Sinopharm was 0.22%, 95% CI: (0.07% to 0.66%), 0.76%, 95% CI: (0.04% to 12.08%), 0.04%, 95% CI: (0.00% to 0.98%), 0.01%, 95% CI: (0.00% to 0.03%), and 0.03%, 95% CI: (0.00% to 18.48%), respectively. Compared to CoronaVac, Pfizer, Moderna, AstraZeneca, and Sinopharm had a higher incidence ratio rate (IRR; 22-times, 76-times, 4-times, and 3-times higher), respectively. Likewise, Pfizer, Moderna, and AstraZeneca showed a higher IRR than Sinopharm (7.3-times, 25.3-times, and 1.3-times higher). The current evidence shows that the incidence rate (IR) of cardiac arrhythmia post-COVID-19 vaccination is rare and ranges between 1 and 76 per 10,000. mRNA vaccines were associated with a higher IR of arrhythmia compared to vector-based vaccines. Inactivated vaccines showed the lowest IR of arrhythmia.
46
Jasim, Rasha Zuhair. "Biochemical Action of Vaccines in Iraqi Patients with COVID-19 Infection." Baghdad Science Journal 20, no. 4(SI) (2023): 1469–79. http://dx.doi.org/10.21123/bsj.2023.8750.
Full textAbstract:
The aim of the present study is to compare the biochemical action of the three vaccines taken in Iraq: Pfizer Biontech, AstraZeneca Oxford and Sinopharm based on biochemical parameters. Seventy COVID-19 Iraqi patients ( males and females ) were participated in the present study and classified into 7 groups : Gc : COVID-19 patients ( without vaccine ) , Gp1: COVID-19 patients took one dose of Pfizer Biontech, Gp2 : COVID-19 patients took two doses of Pfizer Biontech, Ga1 : patients took one dose of AstraZeneca Oxford vaccine , Ga2: patients took two doses of AstraZeneca Oxford vaccine , Gs1 : patients took one dose of Sinopharm vaccine and Gs2: patients took two doses of Sinopharm vaccine. Patients were compared with healthy subjects (without vaccine) as a control group (Gh). The D-dimer level was highly significantly increased in Gc compared with Gh and was highly significantly decreased in Gp1 , Ga1 , Ga2 , significantly decreased in Gp2 and non-significantly decreased in Gs1 and highly significant increased in Gs2 compared with Gc. CRP level was significantly increased in Gc compared with Gh while it was significantly decreased in Gp1, Gp2, Ga1 , Ga2 , Gs1 , Gs2 compared with Gc. IgG and IgM levels were increased in Gc but decreased after taking vaccines ( except Ga2 for IgG and Gp2 for IgM ) The present study submits a novelty to the field of COVID-19 by highlighting the chemical aspects of vaccines used in Iraq
47
Hussein, Nawfal R., Warveen L. Abdulkareem, Narin A. Rasheed, and Mohammed Rashid Ameen. "The Efficacy and Safety of Heterologous Immunization with Pfizer-BioNTech (Pfizer) to Individuals Who Have Completed A Primary Vaccination Schedule with Sinopharm (BBibp-CorV)." Journal of Pure and Applied Microbiology 17, no. 3 (2023): 1783–90. http://dx.doi.org/10.22207/jpam.17.3.43.
Full textAbstract:
The aim of this study was to examine the effectiveness and potential adverse reactions when providing a different Pfizer-BioNTech booster shot to 235 volunteers who had previously received the BBIBP-CorV Sinopharm primary vaccination series. Between February and December 2022, a questionnaire-based cross-sectional study was conducted in Duhok, located within the Kurdistan Region of Iraq. The individuals included in the study were adults aged 18 and above, who had received a Pfizer-BioNTech booster shot following the completion of a two-dose vaccination regimen with Sinopharm (BBIBP-CorV). The findings revealed that among those vaccinated with BBIBP-CorV, there were breakthrough infections at a rate of 4.26%, and no significant correlation was identified between post-vaccination infections and factors such as demographics or medical history. Furthermore, individuals who had a Pfizer booster dose experienced breakthrough infections at a rate of 5.73%, and similarly, no link was discovered between this rate and demographic or medical factors. Additionally, the study uncovered that participants commonly experienced side effects, primarily consisting of mild effects at the injection site. The study implies that both the Sinopharm and Pfizer vaccines demonstrate satisfactory safety profiles. It also suggests that giving a heterologous booster dose to individuals who have finished their primary vaccination with the BBIBP-CorV vaccine offers a significant level of protection against infection.
48
Theresa Pool, Sylvie Nadine, Emelyn Helen Shroff, Agnes Chetty, Lara Lewis, Yende-Zuma Nonhlanhla, and Salim S. Abdool Karim. "Effectiveness of ChAdOx1 nCoV-19 and BBIBP-CorV vaccines against COVID-19-associated hospitalisation and death in the Seychelles infected adult population." PLOS ONE 19, no. 4 (2024): e0299747. http://dx.doi.org/10.1371/journal.pone.0299747.
Full textAbstract:
Background The Seychelles COVID-19 vaccination campaign was initiated using two different vaccines during the first wave of the pandemic in 2021. This observational study estimated vaccine effectiveness against severe outcomes (hospitalisation and/or death) from individuals infected with COVID-19 in the Seychelles adult population during Beta and Delta variant transmission. Methods This nationwide retrospective cohort study included all Seychellois residents aged ≥ 18 years who tested positive by RT-PCR or rapid antigen test for COVID-19 between January 25, 2021, and June 30, 2021. We measured the relative risk (RR) of laboratory-confirmed SARS-CoV-2 hospitalisation and/or death among individuals partially or fully vaccinated with ChAdOx1 nCoV-19 (SII Covishield) or BBIBP-CorV (Sinopharm) vaccines compared to unvaccinated individuals using modified Poisson regression. Controlling for age, gender and calendar month, vaccine effectiveness was estimated as 1-RR ≥14 days after the first dose and ≥7 days after the second dose for each available vaccine versus an unvaccinated control group. Results A total of 12,326 COVID-19 infections were reported in adult Seychellois residents between January 25, 2021, and June 30, 2021. Of these, 1,287 individuals received one dose of either BBIBP-CorV (Sinopharm) or ChAdOx1-nCoV-19 (SII Covishield) vaccine, and 5,225 individuals received two doses. Estimated adjusted effectiveness of two doses of either Sinopharm or SII Covishield was high, at 70% (95% CI 58%–78%) and 71% (95% CI 62%–78%) respectively. Sinopharm maintained high levels of protection against severe outcomes in partially vaccinated individuals at 61% (95% CI 36%–76%), while the effectiveness of one dose of SII Covishield was low at 29% (95% CI 1%–49%). Conclusions This observational study demonstrated high levels of protection of two doses of two vaccine types against severe outcomes of COVID-19 during the first wave of the pandemic driven by Beta (B.1.351) and Delta (B.1.617.2) variant predominance. One dose of ChAdOx1-nCoV-19 (Covishield SII) was found to be inadequate in protecting the general adult population against hospitalisation and/or death from COVID-19.
49
Farhan, Ahmed Abed. "A deep dive into the immunological and hematological responses to COVID-19 vaccines; implications for clinical practice." Immunopathologia Persa 11 (March 30, 2025): 43807. https://doi.org/10.34172/ipp.2025.43807.
Full textAbstract:
Introduction: The COVID-19 pandemic has shown the importance of vaccines in controlling the spread and severity of diseases. The immune responses elicited by different vaccines are important for the assessment of their effectiveness and safety. This study compares immunological and hematological responses to Pfizer, AstraZeneca, and Sinopharm vaccines with unvaccinated subjects to identify patterns and predictors of vaccine-induced immunity. Objectives: This study aimed; 1) to assess the immune and hematological responses induced by Pfizer, AstraZeneca, and Sinopharm vaccines, 2) to compare cytokine levels, IgG production, and leukocyte profiles among vaccine recipients and unvaccinated individuals and 3) to determine the predictors of immune marker activation and finally to characterize response categories through statistical analyses. Patients and Methods: This comparative study analyzed demographic data, leukocyte counts, cytokine levels, and IgG levels from a population vaccinated with Pfizer, AstraZeneca, or Sinopharm vaccines and also included unvaccinated controls. Moreover, multivariate and latent class analysis were conducted to bring out any important predictors and trends of the response. The time comparison until IgG peak levels by groups was established by conducting a survival analysis. Results: Pfizer vaccine recipients had the highest IgG levels (10,489 ± 1167 U/mL) and elevated cytokine levels, including IL-2 (76.73±14.64 pg/mL) and TNF-α (61.96 ± 1.71 pg/mL). AstraZeneca recipients showed increased eosinophil and basophil counts, suggesting mild inflammatory responses. Vaccination was a strong predictor of immune activation (P < 0.001), with distinct responder groups identified through latent class analysis, dominated by Pfizer recipients. Survival analysis showed earlier IgG peak times in vaccinated than in unvaccinated. Conclusion: This is a landmark study defining the differential immunogenicity and safety profiles of Pfizer, AstraZeneca, and Sinopharm vaccines. Pfizer showed the strongest immune activation, while AstraZeneca revealed mild subclinical inflammation. These results provide key insights into vaccine-induced immunity, which support their safe and effective administration in fighting against COVID-19.
50
Dong, Bo, Shiyang Zhu, Ying Song, Shaowei Guan, Jinhui Pang, and Zhenghua Jiang. "Synthesis of poly(arylene ether ketone) containing phenylsulfonic acid pendant for proton exchange membrane." High Performance Polymers 29, no. 10 (2016): 1232–40. http://dx.doi.org/10.1177/0954008316674343.
Full textAbstract:
A series of phenylsulfonic acid–containing poly(arylene ether ketone) (psa-PAEK) were synthesized via polycondensation from 2-(4-methoxy)phenylhydroquinone and other commercial monomers, followed by postsulfonation approach under mild reaction conditions. Controlled substituted sites and the degree of sulfonation were realized using quantities of 2-(4-methoxy)phenylhydroquinone. Giving the psa-PAEK can be soluble in common organic solvents such as Dimethylsulfoxide, purity ≥99.5% (DMSO, Sinopharm Chemical Reagent Co., Ltd, Shanghai, China), NMP, 1-Methyl-2-pyrrolidinone purity ≥99.0% (NMP, Sinopharm Chemical Reagent Co., Lted, Shanghai, China), and N,N-dimethylacetamide, purity ≥99.0% (DMAc, Sinopharm Chemical Reagent Co., Lted, Shanghai, China). The tough and transparent polymer membrane was prepared by the solution casting method, which exhibited excellent mechanical properties and high proton conductivities. The tensile stress at maximum load and elongation at break of these membranes are 28.3–34.1 MPa and 101–126% in dry state, respectively. The proton conductivities of these membranes were higher than 10−2 S cm−1 at room temperature in water. Especially, the psa-PAEK-90 with ion exchange capacity of 1.62 mequiv. g−1 exhibited the proton conductivity of 176 mS cm−1 at 80°C in water. The clear microphase separation morphology was observed by small-angle X-ray scattering, which is a powerful evidence to explain their high conductive behaviors. These results suggest that the psa-PAEK membranes have great potential as a candidate membrane for proton exchange membrane fuel cell applications.